Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of FCGR3B monoclonal antibody, clone MEM-154 (Biotin)
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Mouse |
| Applications | Flow Cyt |
More info about FCGR3B monoclonal antibody, clone MEM-154 (Biotin)
| Brand: | Abnova |
| Reference: | MAB4538 |
| Product name: | FCGR3B monoclonal antibody, clone MEM-154 (Biotin) |
| Product description: | Mouse monoclonal antibody raised against native FCGR3B. |
| Clone: | MEM-154 |
| Isotype: | IgG1 |
| Gene id: | 2215 |
| Gene name: | FCGR3B |
| Gene alias: | CD16|CD16b|FCG3|FCGR3 |
| Gene description: | Fc fragment of IgG, low affinity IIIb, receptor (CD16b) |
| Immunogen: | Native purified FCGR3B from human granulocytes. |
| Form: | Liquid |
| Recommend dilutions: | Flow Cytometry (1:500) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS, pH 7.2 (0.09% sodium azide) |
| Storage instruction: | Store at 4°C. Do not freeze. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Conjugate tag: | Biotin |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Specificity: | This antibody reacts with the epitope on CD16 antigen that residing in proximity to FG loop (probably BC or C'E loop). This antibody reacts with CD16+ granulocytes. |
| Reactivity: | Human |
| Applications: | Flow Cyt |
| Shipping condition: | Blue Ice |
| Publications: | IgE-mediated activation of NK cells through Fc gamma RIII.Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T. J Immunol. 2003 Mar 15;170(6):3054-8. |